Keren S, et al. - Researchers performed a retrospective study of patients with aminobisphosphonate-associated orbital/ocular inflammation to investigate their demographics, clinical presentation, disease course, and treatment. In addition, they undertook a literature review to differentiate disease presentation and course between various aminobisphosphonates. Zoledronate, alendronate and risedronate were the used drugs. The analysis of 8 patients from their institution (6 women and 2 men, median age 62 years) revealed that conjunctival hyperaemia/chemosis was the most common clinical presentation and scleritis was the most common manifestation, followed by diffuse orbital inflammation and anterior uveitis. Observations revealed that mostly intravenous aminobisphosphonates cause orbital/ocular inflammation. Risedronate was not identified inducing uveitis. They recommend halting the putative aminobisphosphonate at the onset of orbital/ocular involvement and identified prognosis as favourable.